Skip to search formSkip to main contentSkip to account menu

rucaparib

National Institutes of Health

Related topics

Related topics

8 relations

Narrower (3)

AG 014699PF-01367338Rubraca

Broader (2)

IndolesPoly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-Ribose) Polymerase Inhibitors [MoA]rucaparib 200 MG Oral Tablet [Rubraca]rucaparib 300 MG Oral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian…
Background: The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib has demonstrated clinical activity in patients with… 
2019
2019
Abstract 3888: Intracranial evaluation of the in vivo pharmacokinetics, brain distribution, and efficacy of rucaparib inBRCA-mutant, triple-negative breast cancer
Background: The poly(ADP-ribose) polymerase inhibitor rucaparib is approved for use in recurrent ovarian cancer; however, there… 
2017
2017
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS
Poly(adenosine diphosphate ribose) polymerases (PARPs) are multifunctional proteins which play a role in many cellular processes… 
2017
2017
An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.
TPS1117Background: BRCA1 and/or BRCA2 mutations confer sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). In… 
2017
2017
Rucaparib Approved for Ovarian Cancer.
The FDA approved the PARP inhibitor rucaparib to treat women with advanced ovarian cancer who have already been treated with at… 
2017
2017
Approvals in 2016: cost–benefit challenges of new anticancer agents
In 2016, four new anticancer drugs were approved by the FDA, and a further 12 existing agents were approved for 14 additional… 
2014
2014
ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.
TPS5619 Background: PARP inhibitors (PARPi) are active in patients (pts) with mutations in BRCA, a critical component of… 
2014
2014
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
Background:Patients with malignant pleural effusions (MPEs) generally have advanced disease with poor survival and few… 
2014
2014
Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.
2013
2013
A phase I study of oral rucaparib in combination with carboplatin.
2586 Background: Targeting poly (ADP-ribose) polymerase (PARP), an enzyme involved in DNA damage repair, may increase efficacy of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)